

To:
Orphan Medicines Office, European Medicines Agency
[Submit via IRIS secure online portal](#)

Copy:
B5 - Medicines: policy, authorisation and monitoring, European Commission
sante-pharmaceuticals-B5@ec.europa.eu

Subject: name/address change of the sponsor of orphan designation(s):

- *product name for indication, EU designation number, INN (recommended only)*
- *product name for indication, EU designation number, INN (recommended only)*

In accordance with Point G.2 of the European Commission (EC) Guideline on the format and content of applications for the designation(s) as orphan medicinal products (ENTR/6283/00) please be informed about a change in the sponsor's contact details. The sponsor remains the same legal entity. The details of the initial and new contact details are reported below.

Sponsor	Initial details	New details
Name of company		
Address of company tel/fax numbers		
Name, company, address, email and tel/fax numbers of contact person for communication with the EMA and the EC ¹		
Name, company, address, email and tel/fax numbers of contact person for inquiries from interested parties or		
E-mail address for general public inquiries		

Signed by authorised representative:

Printed name: _____

Signature: _____

Date: _____

¹ When the person authorised to communicate with the EMA and the EC on behalf of the sponsor represents a third party (e.g. a consulting company or an individual), a letter of authorisation stating the contact point should be provided by the sponsor (in PDF format).
